In October 2015, the European Commission issued “A Single Market Strategy for Europe” COM(2015) 550 final. One of goals of this strategy is to consolidate Europe’s IP framework. For the pharmaceutical industry, the question arises as to how the upcoming unitary patent will work together with the national SPCs.
The Commission indicated that it will consider initiatives:
- To address uncertainties about how the unitary patent will work together with current EU rules on SPCs;
- In relation to the scope of the ‘Bolar’ and research exemptions in view of the upcoming establishment of the Unified Patent Court;
- To introduce targeted SPC manufacturing waiver for export purposes.
That is why our Brussels life sciences experts are organising a seminar dedicated to these important topics. The seminar aims to present to present the current legal landscape and legal implications of the foreseen developments at both European and international levels to professionals of the pharmaceutical industry.
Below you will find an outline of the main topics that are discussed during the seminar.